Biomodifying

Biomodifying is a biotechnology company based in Cambridge, UK, specializing in the development of a proprietary platform for site-specific protein modification. The company's technology is designed to enable the precise attachment of drugs, fluorophores, or other functional groups to antibodies and proteins, facilitating the creation of homogeneous and stable biotherapeutics. Founded by Dr. John McCafferty, a co-founder of Cambridge Antibody Technology, Biomodifying leverages deep expertise in antibody engineering to address challenges in the development of antibody-drug conjugates (ADCs). The platform aims to enhance the safety and efficacy of biologics by providing better control over the conjugation process. Biomodifying primarily focuses on oncology applications and collaborates with other biotech entities to advance next-generation protein-based therapies.